NDT Advance Access published February 3, 2007

Size: px
Start display at page:

Download "NDT Advance Access published February 3, 2007"

Transcription

1 NDT Advance Access published February 3, 2007 Nephrol Dial Transplant (2007) 1 of 6 doi: /ndt/gfl840 Original Article Implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease after the introduction of cinacalcet in a population of patients on chronic haemodialysis Maria Dolores Arenas 1, Fernando Alvarez-Ude 2, Maria Teresa Gil 1, Analía Moledous 1, Tamara Malek 1, Carlos Nun ez 1, Ramo n Devesa 1, Maria Antonia Carreto n 1 and Antonio Soriano 1 1 Nephrology Department, Hospital Perpetuo Socorro, Plaza Dr Gomez ulla, 15, Alicante and 2 Hospital General, Segovia, Spain Abstract Background. The purpose of the present study was to evaluate the impact of cinacalcet administration on the attainment of Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation (NFK-K/DOQI) targets, in a group of dialysis patients with secondary hyperparathyroidism that were not controlled with vitamin D metabolites due to inadequate elevations in serum calcium and/or phosphorus. Methods. Twenty-eight patients undergoing haemodialysis that presented secondary hyperparathyroidism (PTH > 300 pg/ml) with difficulty to use vitamin D either because of hypercalcaemia (>10.2 mg/dl) and/or hyperphosphoraemia (>5.5 mg/dl) were included in this study. The follow-up period was 9 months before and after the introduction of cinacalcet. We started by adding 30 mg of cinacalcet orally once daily to their previous vitamin D metabolite treatment. The following variables were calculated and recorded: the mean of all measurements of serum Ca, P and parathyroid hormones (PTH), and Ca P in each patient; calcium in dialysate (meq/l); doses of vitamin D administered; doses of cinacalcet used, and the average prescription of calcium based phosphate binders, sevelamer hydrochloride and aluminum binders, corresponding to two periods according to the introduction of cinacalcet. The proportions of patients with different serum Ca levels as well as serum P levels; serum PTH levels and CaxP at the beginning and at the end of the nine month period of treatment with cinacalcet were calculated. Results. Serum PTH ( vs , P < 0.001), serum calcium ( vs , Correspondence and offprint requests to: M. D. Arenas, Hospital Perpetuo Socorro, Plaza Dr Go mez Ulla, 15, Alicante, Spain. lola@olemiswebs.com; arenasd@perpetuosocorro.nehos.com P < 0.001) and the Ca P product ( vs ; P < 0.001) diminished significantly whereas serum phosphorus remained unchanged ( vs ; P ¼ NS). Before cinacalcet, 23 patients had severe hyperparathiroidism (serum PTH > 500) and 15 patients hypercalcaemia (serum calcium >10.2 mg/dl). After 9 months of treatment, all 28 patients showed serum PTH < 500 pg/ml and serum calcium <10.2 mg/dl; 64.7% of the patients achieved Ca, P, Ca P and PTH objectives simultaneously. While the mean dose of cinacalcet increased along the 9 months of treatment (P < 0.001), there were no significant changes in vitamin D metabolites (P ¼ 0.5), neither in the mean doses of calciumcontaining agents, nor in the mean prescribed doses of sevelamer (P < 0.01), and aluminium-containing agents diminished significantly (P < 0.05). Conclusions. In summary, the combination of cinacalcet and low doses of vitamin D improved significantly the control of PTH and Ca P in patients with severe secondary hyperparathiroidism on chronic haemodialysis, without adverse effects and with lower doses of phosphate binders. Keywords: bone metabolism; calcium; calcimimetics, K/DOQI targets; PTH; vitamin D Introduction The K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Renal Disease were published in October 2003 [1], but assessment of the results obtained from the application of those guidelines is essential for evaluating their true applicability and the consequences of its application. A previous study [2], carried out before calcimimetics was available in Spain, and based on monitoring of ß The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org

2 2of6 quality indicators following the publication of the K/DOQI Guidelines, showed that in spite of the application of K/DOQI recommendations, a large proportion of our patients remained outside the proposed targets and pointed to the need for more effective therapeutic options. Calcimimetics suppress the secretion of parathyroid hormone (PTH) by increasing the sensitivity of the calcium receptors of parathyroid cells to extracellular ionized calcium [3]. Cinacalcet HCL was recently approved by the US FDA and European Medicines Agency for treatment of secondary hyperparathyroidism of dialysis patients [4,5]. A recent study showed that cinacalcet-treated subjects were more likely to achieve the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation (NFK-K/DOQI) recommended goals for CaxP (65%) and concurrent CaxP and PTH (41%) [6]. Post-hoc analysis of long-term data from 1184 patients has shown that cinacalcet HCl treatment might reduce the risk of parathyroidectomy compared with placebo [7]. The purpose of the present study was to evaluate the impact of cinacalcet administration on the attainment of NFK-K/DOQI targets, in a group of dialysis patients with secondary hyperparathyroidism that were not controlled with vitamin D metabolites due to inadequate elevations in serum calcium and/or phosphorus. Methods Patients The criteria for using calcimimetics in our unit are secondary hyperparathyroidism (PTH > 300 pg/ml) with difficulty to use vitamin D either because of hypercalcaemia (>10.2 mg/dl) and/or hyperphosphoraemia (>5.5 mg/dl). The exclusion criteria is a serum calcium <8.4 mg/dl. All the 28 patients undergoing haemodialysis in our unit that presented such criteria were included in this study. The follow-up period was 9 months after the introduction of cinacalcet. All patients received regular haemodialysis sessions, lasting from 3.5 to 4 h, three times weekly, using m 2 polysulphone dialysers of varying permeability. They were all maintained in a stable haemodialysis regimen and similar schedule of dialysis in all studied periods. Objectives, quality standards and NFK-K/DOQI recommendations From October 2003, NFK-K/DOQI recommendations were introduced in our haemodialysis units and the objectives were to maintain PTH levels between 150 and 300 pg/ml (Guideline 1.4), serum Ca levels between 8.4 and 9.5 mg/dl (Guideline 6.2), P levels between 3.5 and 5.5 mg/dl (Guideline 3.2), and Ca P <55 mg 2 /dl 2 (Guideline 6.5). Guidelines 7 and 8 state that vitamin D metabolites should be reduced or discontinued if serum calcium levels are >10.2 mg/dl, phosphorus levels are >5.5 mg/dl, the Ca P product is >55 mg 2 /dl 2, or PTH levels are decreased <150 pg/ml (Guideline 7). Guideline 5 states that the total dose of elemental calcium provided by the calcium-based phosphate binders should not exceed 1500 mg/day and that non-calcium-containing phosphate binders are preferred in dialysis patients with severe vascular and/or other soft-tissue calcifications. Guideline 9 recommends the use of dialysates with a calcium content of 2.5 meq/l. Treatments In those 28 patients, we started by adding 30 mg of cinacalcet orally once daily to their previous vitamin D metabolite treatment (Alphacalcidol: Etalpha Õ ; Leo Pharma) that was being given in intravenous pulses immediately after haemodialysis sessions. When NFK-K/DOQI recommendations were introduced, a 2.5 meq/l dialysate calcium concentration was preferentially used; but after calcimimetric introduction the dialysate calcium content changed to 3 meq/l in order to avoid the hypocalcaemia associated with cinacalcet administration. A combination of calcium-based phosphatebinding agents (calcium acetate), aluminium-containing phosphate-binding agents (aluminium hydroxide) and non-calcium, non-aluminium, non-magnesium-containing phosphate-binding agents (sevelamer) were used to achieve the serum P target: such schedule was initially maintained without changes when cinacalcet was introduced. Doses were adjusted according to patient response. Criteria for vitamin D metabolites and/or cinacalcet dosage adjustment were based on the K/DOQI Guideline s recommended levels of calcium, phosphorus and/or PTH. When PTH levels were >300 pg/ml, if serum calcium was <8.4 mg/dl and there was no hyperphosphoraemia (phosphorus >5.5 mg/dl), the dose of vitamin D was increased; if serum calcium was >9.5 mg/dl or serum phosphorus >5.5 mg/dl, the dose of cinacalcet was increased. In the case of PTH < 150 pg/ml, the dose of vitamin D metabolites or cinacalcet were reduced to calcium and/or phosphorus levels as previously stated. The objective was to maintain a combination of the lowest possible doses of both drugs, in order to reach the K/DOQI recommended objectives with minimal side-effects. Monitoring M. D. Arenas et al. PTH was routinely measured every 2 months, and serum Ca and P levels, every month. In patients in whom drug dosage changes were made or calcimimetics were introduced, PTH, Ca, and P were measured more frequently (PTH monthly, and calcium and phosphorus weekly or biweekly). The following variables were calculated and recorded: the mean of all measurements of serum Ca, P and PTH, and Ca P in each patient; calcium in dialysate (meq/l); doses of vitamin D administered; doses of cinacalcet used, and the average prescription of calcium-based phosphate binders (expressed as milligrams of elemental calcium/day), sevelamer hydrochloride (expressed as number of sevelamer 800 mg tablets/day) and aluminum binders, corresponding to two periods according to the introduction of cinacalcet: the 9 months before (pre-cinacalcet period) and the 9 months after (post-cinacalcet period). The proportions of patients with different serum Ca levels were calculated: <8.4 mg/dl, between 8.4 and 9.5 mg/dl, between 9.5 mg/dl and 10.2 mg/dl and >10.2 mg/dl; as well as serum P levels less than and >5.5 mg/dl; serum PTH levels

3 K/DOQI Guidelines for bone metabolism and disease 3 of 6 <150 pg/ml, between 150 and 300 pg/ml, between 300 and 500 pg/ml and >500 pg/ml; and Ca P less than and >55 mg 2 /dl 2 at the beginning and at the end of the 9 month period of treatment with cinacalcet. Laboratory tests Calcium (by UV-Vis spectrophotometry; normal laboratory range, mg/dl), phosphorus (by UV-Vis spectrophotometry; normal laboratory range, mg/dl) and intact PTH (using an electro-chemoluminescence technique; normal laboratory range, pg/ml) were measured just before the mid-week dialysis session. There were no changes in laboratory techniques and commercial kits used in both periods. Statistical analysis The statistical analysis was carried out with SPSS 12.1 software. A paired Student s t-test was used to compare the means of all Ca, P, Ca P and PTH measurements in every patient in both periods. Percentages were compared using a Mc Nemar test. The statistical significance level used was P < Results Demographic characteristics The mean age at the beginning of study was years, and the mean time on haemodialysis was months; 18 patients (64.2%) were male and 10 patients (35.7%) were female. No significant differences were found in mean sktv levels and mean haemoglobin values between the pre-cinacalcet ( and g/dl, respectively) and the post-cinacalcet ( and g/dl, respectively) periods. Comparison between the pre- and post-cinacalcet periods Following the introduction of cinacalcet treatment, there was a significant decrease in mean serum PTH ( pre-cinacalcet period and post-cinacalcet period; P < 0.05); mean pre-dialysis serum calcium levels ( pre-cinacalcet period and post-cinacalcet period; P < 0.001); mean serum phosphorus levels ( pre-cinacalcet period and post-cinacalcet period; P < 0.01) and calcium phosphorus product ( pre-- cinacalcet period and post-cinacalcet period; P < 0.01) In the post-cinacalcet period, mean dialysate calcium content increased ( pre-cinacalcet period and post-cinacalcet period; P < 0.001), and mean vitamin D metabolite doses decreased significantly ( pre-cinacalcet period and postcinacalcet period; P < 0.05). At the same time the mean prescribed dose of sevelamer significantly decreased ( tablets/day pre-cinacalcet period and tablets/day post-cinacalcet period; P < 0.05) whereas the mean prescribed daily amount of elemental calcium remained unchanged ( pre-cinacalcet period and post-cinacalcet period; P ¼ NS). Achievement of NFK-K/DOQI recommended goals Table 1 shows the changes in serum levels of PTH, calcium, phosphorus and Ca P after the introduction of cinacalcet. As it can be seen, serum PTH, serum calcium and the Ca P product diminished significantly whereas serum phosphorus remained unchanged. Before cinacalcet, 23 patients had severe hyperparathiroidism (serum PTH > 500) and 15 patients hypercalcaemia (serum calcium >10.2 mg/dl). After 9 months of treatment, all 28 patients showed serum PTH < 500 pg/ml and serum calcium <10.2 mg/dl. Table 2 shows the percentages of achievement of NFK-K/DOQI recommended goals, at the time of cinacalcet introduction (month 0) and at the end of the 9 months of cinacalcet treatment. Changes in the different components of bone metabolism treatment Table 3 shows the evolution of the different components of bone metabolism treatment after the introduction of cinacalcet. While the mean dose of cinacalcet increased along the nine months of treatment, there were no significant changes in vitamin D metabolites neither in the mean doses of calcium-containing agents, nor in the mean prescribed doses of sevelamer, and aluminium-containing agents diminished significantly. At the end of the study, 12 patients had increased the dose of alfacalcidol by mcg/session, four patients maintained the same dose, and 12 patients diminished the dose in mcg/session. Table 1. Changes in mean serum levels of PTH, calcium and phosphorus after the introduction of cinacalcet Cinacalcet 0 months Cinacalcet 4 months Cinacalcet 9 months P* Serum PTH (pg/ml) <0.001 Serum calcium (mg/dl) <0.001 Serum phosphate (mg/dl) Phosphate calcium (mg2/dl2) <0.001 *P-value refers to the comparison between the start (0 months) and the end (9 months) of cinacalcet treatment.

4 4of6 M. D. Arenas et al. Table 2. Percentages of achievement of the NFK-K/DOQI recommended goals before (0 months) and after (9 months) cinacalcet treatment (n ¼ 28 patients) Before cinacalcet (0 months) After cinacalcet (9 months) P Patients with PTH between 150 and 300 pg/ml (%) <0.001 Patients with calcium <9.5 mg/dl (%) <0.001 Patients with posphorus <5.5 mg/dl (%) <0.05 Patients with CaP <55 mg/dl 2 (%) <0.05 Patients with simultaneous Ca, P and PTH goal achievement (%) <0.001 Table 3. Changes in the different components of bone metabolism treatment after the introduction of cinacalcet Cinacalcet 0 months Cinacalcet 4 months Cinacalcet 9 months P* Vitamin D metabolites (mcg/week) Ca-containing agents (mg Ca þþ /day) Sevelamer 800 mg (tablets/day) <0.01 Aluminium-containing agents (tablets/day) <0.05 Calcium in dialysate (meq/l) <0.05 Cinacalcet dose (mg/day) <0.001 *P-value refers to the comparison between the start (0 months) and the end (9 months) of cinacalcet treatment. The dose of cinacalcet at the end of the 9 months was 30 mg in 17 patients, 60 mg in eight patients, 90 mg in two patients and 120 mg in one patient. Three patients complained of gastrointestinal discomfort (nausea/vomiting and diarrhoea) that improved after nightly administration of cinacalcet. No clinical signs or symptoms of hypocalcaemia (muscle spasms, confusion or abdominal pain) were reported. Two consecutive measurements of serum Ca <8.4 mg/dl were reported in three patients and two consecutive measurements of serum Ca <7.5 mg/dl were reported in two subjects. No patient was withdrawn from the study due to hypocalcaemia. At the beginning of cinacalcet treatment, all 28 patients were changed to a dialysate with a calcium content of 3.0 meq/l; after 9 months, 12 patients could be changed to a dialysate with 2.5 meq/l of calcium. At the end of the study 85.7% of the patients were using sevelamer; 50% calcium-containing agents and 28.5% aluminium-containing agents. After the introduction of cinacalcet the mean monthly cost per patient increased by 192 euros; at 9 months the cost could be reduced by 21.4 euros due to the reduction in sevelamer and alphacalcidol doses (Table 4). Discussion The 2003 guidelines for the management of hyperparathyroidism in chronic kidney diseases compiled by NFK-K/DOQI were formulated on the basis of work published up until 2001, before calcimimetics was available. Guideline 6 states that, in patients with stage 5 CKD: (i) corrected serum calcium levels should be kept within the normal laboratory range, preferably in the lower limit (between 8.4 and 9.5 mg/dl); (ii) the Ca P product should be kept below 55 mg 2 /dl 2 ; (iii) if corrected Ca levels exceed 10.2 mg/dl, oral calcium sources should be suppressed. Guidelines 7 and 8 state that vitamin D metabolites should be reduced or discontinued if serum calcium levels are >10.2 mg/dl, phosphorus levels are >5.5 mg/dl, the Ca P product is >55 mg 2 /dl 2 or PTH levels are decreased <150 pg/ml (Guideline 7). Guideline 5 states that the total dose of elemental calcium provided by the calcium-based phosphate binders should not exceed 1500 mg/day and that non-calcium-containing phosphate binders are preferred in dialysis patients with severe vascular and/or other soft-tissue calcifications. Guideline 9 recommends the use of dialysates with a calcium content of 2.5 meq/l [1]. Previous studies [2], carried out in our unit, showed that the application of the K/DOQI recommendations resulted in the following changes: (i) a decreased use of dialysates with a calcium content of 3.0 and 3.5 meq/l and an increased use of concentrates with 2.5 meq/l of calcium; (ii) a decreased prescription of calcium salts as phosphate binding agents, and an increased prescription of sevelamer (a non-calcium, non-aluminium, non-magnesium-containing phosphate binding agent) and (iii) a diminution and/or discontinuation of vitamin D in patients whose calcium levels were over the new objectives defined in K/DOQI guidelines. Positive and negative consequences after applying the DOQI guidelines were observed. As positive consequences, Ca decreased significantly, as did the percentage of patients with Ca > 10.2 mg/dl, in relation to a decrease in Ca provision in the form of calcium chelating agents and vitamin D. As negative consequences, the PTH levels, the percentage of patients with severe secondary hyperparathyroidism, and the serum P levels all increased. At that time we concluded that current

5 K/DOQI Guidelines for bone metabolism and disease 5 of 6 Table 4. Mean monthly cost per patient before and after the introduction of cinacalcet Euros month before cinacalcet Euros month 1 month cinacalcet Euros month 9 months cinacalcet P Alphacalcidol <0.001 Royen 500 mg Sevelamer 800 mg <0.01 Aluminium-containing agents <0.05 Cinacalcet <0.001 Total <0.001 therapeutic strategies based on vitamin D compounds and calcium-containing phosphate binders are difficult to implement effectively because both agents are associated with substantial, and often dose-limiting, calcaemic actions that prevent the attainment of treatment targets. In fact, the 28 patients included in the present study were those that had shown the worse results after the implementation of the K/DOQI guidelines: their mean serum PTH had increased from to (P < 0.001). From January 2006, calcimimetics were available in our unit. Calcimimetics are novel agents that increase the sensitivity of calcium-sensing receptors in the parathyroid glands. Consequently, they allow simultaneous reduction of both PTH and extracellular calcium concentrations, thus differing from currently available vitamin D therapies [3 5]. Reduction of the calciumphosphorus product (Ca P) is a consistent feature of calcimimetic therapy and may facilitate the achievement of secondary hyperparathyroidism treatment targets [8]. In this study, the combined use of cinacalcet and vitamin D metabolites improved the achievement of K/DOQI objectives, and particularly the control of patients with severe hyperparathyroidism. In fact, 64.7% of the patients achieved Ca, P, Ca P and PTH objectives simultaneously. Using traditional therapies, only a small fraction (6%) of patients can be brought within all four of the K/DOQI biochemical goals [9]. The combined use of vitamin D metabolites and cinacalcet allowed for the use of lower doses of both drugs: mean doses at 9 months were 2.9 mcgs/week for alfacalcidol and 62.3 mg/day for cinacalcet. The majority of patients reached K/DOQI objectives with 30 mg of cinacalcet; only one patient needed 120 mg/day. These relatively low doses, probably contributed to the scarce number of secondary effects due to both drugs. There was a significant reduction in the number of episodes of hypercalcaemia (the percentage of patients with Ca >10.2 mg/dl was 52.9% before cinacalcet and 0% after cinacalcet) and hyperphosphoraemia (the percentage of patients with serum phosphorus >5.5 mg/dl was 29.4% before and 11.7% after cinacalcet). Only three patients complained of gastrointestinal discomfort that improved after changing the time of administration of cinacalcet to bedtime (we do not know the reason for this effect of change in time administration). We only detected six asymptomatic hypocalcaemic episodes in five patients. No patient had to stop cinacalcet due to secondary effects. Besides, recent evidence has suggested that vitamin D can have numerous other physiological functions, including protection against certain autoimmune diseases, such as diabetes and multiple sclerosis, and inhibition of proliferation of a number of malignant cells including breast and prostate cancer cells [10], which might be another reason to justify the combined use of both drugs. The calcimimetic cinacalcet sensitizes the parathyroid cells to the extracellular calcium signal, suppressing PTH release and synthesis and preventing parathyroid cell proliferation. This primary PTH suppression decreases the release of calcium and phosphate from bone without increasing intestinal absorption of calcium and phosphate. Therefore, cinacalcet increases the risk of hypocalcaemia. This could justify its combined use with high doses of calcium-containing oral phosphate binders and a dialysate calcium concentration of up to 3.5 meq/l, in order to prevent hypocalcaemia. Nevertheless, the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) has recommended restriction of supplemental elemental calcium to 1.5 g/day (Guideline 5) and Guideline 9 recommends the use of dialysates with a calcium content of 2.5 meq/l. In fact, in this study, after a few months of combined treatment, the mean dose of calciumcontaining oral phosphate binders could be stablized and were well below the 1500 mg/day recommended in K/DOQI guidelines. The recommendation of a routine dialysate calcium concentration of up to 2.5 meq/l (Guideline 9), is controversial [11] since concentrations within this range might stimulate PTH and exacerbate radiological osteitis fibrosa cystica. In fact, various studies have shown an inverse association between PTH levels and calcium concentrations in dialysate, as well as a worsening of secondary hyperparathyroidism in dialyzed patients with low calcium content in the dialysate [12,2], probably as a consequence of the stimulating effect on PTH of negative calcium balance during the haemodialysis session. Administration of calcimimetics, which decrease serum calcium levels, permits the use of a higher dialysate calcium concentration. At the beginning of this study, we decided to

6 6of6 increase the calcium in the dialysate from 2.5 meq/l to 3.0 meq/l, with the intention of avoiding the probable hypocalcaemias described with cinacalcet. We did not need to use higher calcium containing dialysates (3.5 meq/l), and most patients were kept on 3.0 meq/l baths, that assures a neutral or slightly positive calcium balance during dialysis; in fact, at the end of the study 42.8% of the patients were using a 2.5 meq/l dialysate. A collateral effect of cinacalcet treatment was a better control of phosphate levels, as it has been described by others [13,14] that allowed for a reduction in the doses of phosphate binding agents: sevelamer dose diminished from a mean of tablets/day and aluminium-containing agents passed from 2.7 to 1.4 tablets/day. The use of cinacalcet increased significantly the costs of treatment in these patients. Nevertheless, the achievement of objectives improved drastically at the same time, as there was a significant reduction in the frequency of undesirable effects. Further studies are needed to evaluate the impact of this treatment on morbimortality so as to be able to calculate the relationship between costs and benefits of the combined use of both vitamin D metabolites and cinacalcet vs cinacalcet alone. In summary, the combination of cinacalcet and low doses of vitamin D significantly improved the control of PTH and CaxP in patients with severe secondary hyperparathiroidism on chronic haemodialysis, without adverse effects and with lower doses of phosphate binders. Conflict of interest statement. None declared. References 1. National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42[Suppl 3]: S1 S Arenas MD, Alvarez-Ude F, Gil MT et al. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Trasplant 2006; 21: Hofer AM, Brown EM. Extracelullar calcium sensing and signalling. Nat Rev Cell Biol 2003; 4: Shahapuni I, Mansour J, Harbouche L et al. How do calcimimetics fit into the management of parathyroid hormone, calcium and phosphate disturbances in dialysis patients? Semin Dial 2005; 18: Lindberg JS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney int 2005; 67: Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/ DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44[5 Suppl 2]: Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004; 26: K/DOQ Clinical Practice Guidelines for Bone Metabolism and Disease in chronic in Chronic Kidney Disease. With comments from: Cannata-Andı a J, Coen G, Cuninghan J, London G, Olgaard K. Published by OCC Europe Ltd on behalf of Amgen (Europe) Fiedler R, Deuber HJ, Langer T, Osten B, Mohan S, Jehle PM. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients. Nephron Clin Pract 2004; 96: Strippoli GF, Palmer S, Palmer S et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 2006; 47: Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: Received for publication: Accepted in revised form: M. D. Arenas et al.

Original Article. Introduction

Original Article. Introduction Nephrol Dial Transplant (2006) 21: 1663 1668 doi:10.1093/ndt/gfl006 Advance Access publication 6 February 2006 Original Article Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism

More information

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral

More information

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes ..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol

More information

Clinical Guideline Bone chemistry management in adult renal patients on dialysis

Clinical Guideline Bone chemistry management in adult renal patients on dialysis Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L

More information

New Medicines Profile. December 2013 Issue No. 13/04. Colestilan

New Medicines Profile. December 2013 Issue No. 13/04. Colestilan New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic

More information

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker

More information

Therapeutic golas in the treatment of CKD-MBD

Therapeutic golas in the treatment of CKD-MBD Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral

More information

Sensipar. Sensipar (cinacalcet) Description

Sensipar. Sensipar (cinacalcet) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)

More information

The Parsabiv Beginner s Book

The Parsabiv Beginner s Book The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism

More information

Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)

Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism

More information

2017 KDIGO Guidelines Update

2017 KDIGO Guidelines Update 2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES

More information

New biological targets for CKD- MBD: From the KDOQI to the

New biological targets for CKD- MBD: From the KDOQI to the New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr

More information

Month/Year of Review: September 2012 Date of Last Review: September 2010

Month/Year of Review: September 2012 Date of Last Review: September 2010 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1

Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative

More information

The role of calcimimetics in chronic kidney disease

The role of calcimimetics in chronic kidney disease http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL

More information

Sensipar (cinacalcet)

Sensipar (cinacalcet) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Contents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian

Contents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist

More information

Velphoro (sucroferric oxyhydroxide)

Velphoro (sucroferric oxyhydroxide) STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney

More information

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,

More information

Kobe University Repository : Kernel

Kobe University Repository : Kernel Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms

More information

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker

More information

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea

More information

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro ) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:

Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study Forni Valentina¹, Pruijm Menno¹,

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions

More information

Guidelines and new evidence on CKD - MBD treatment

Guidelines and new evidence on CKD - MBD treatment Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,

More information

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among

More information

Treatment Options for Chronic Kidney

Treatment Options for Chronic Kidney Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition

More information

TRANSPARENCY COMMITTEE OPINION. 22 July 2009

TRANSPARENCY COMMITTEE OPINION. 22 July 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL

More information

Secondary hyperparathyroidism in dialysis patients

Secondary hyperparathyroidism in dialysis patients Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++

More information

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement

More information

Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer

Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1

More information

qthis medicinal product is subject to additional monitoring. This will allow quick identification of new safety

qthis medicinal product is subject to additional monitoring. This will allow quick identification of new safety Parsabiv q (etelcalcetide) Frequently Asked Questions qthis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals

More information

CKD-MBD CKD mineral bone disorder

CKD-MBD CKD mineral bone disorder CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Calcium x phosphate product

Calcium x phosphate product Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL

More information

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia NSW Therapeutic Advisory Group Level 5, 376 Victoria Street PO Box 766 Darlinghurst NSW 2010 Phone: 61 2 8382 2852 Fax: 61 2 8382 3529 Email: nswtag@stvincents.com.au www.nswtag.org.au Drugs for the treatment

More information

Simultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl

Simultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl Simultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl Stuart M. Sprague,* Pieter Evenepoel, Mario P. Curzi, Maria Teresa González, Fred E. Husserl, Nelson

More information

Should cinacalcet be used in patients who are not on dialysis?

Should cinacalcet be used in patients who are not on dialysis? Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.

More information

Use of magnesium as a drug in chronic kidney disease

Use of magnesium as a drug in chronic kidney disease Clin Kidney J (2012) 5[Suppl 1]: i62 i70 doi: 10.1093/ndtplus/sfr168 Use of magnesium as a drug in chronic kidney disease Alastair J. Hutchison 1 and Martin Wilkie 2 1 University of Manchester and Manchester

More information

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic

More information

Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis

Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and

More information

Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through

Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol

More information

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only) 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National

More information

PARSABIV (etelcalcetide)

PARSABIV (etelcalcetide) PARSABIV (etelcalcetide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and

More information

Tenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia

Tenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia , a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3

More information

Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW

Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW Introduction Brand name: Parsabiv Generic name: Etelcalcetide Pharmacological class: Calcimimetic Strength and Formulation: 2.5mg/0.5mL, 5mg/mL, 10mg/2mL;

More information

Key words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis

Key words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet

More information

Cinacalcet treatment in advanced CKD - is it justified?

Cinacalcet treatment in advanced CKD - is it justified? Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to

More information

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu

More information

Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)

Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) RMP Summary: Version 1, November 2017 EU RMP: Version 1.0, November 2016 Page 1 of 6 The Risk Management Plan (RMP) is a comprehensive

More information

Normal kidneys filter large amounts of organic

Normal kidneys filter large amounts of organic ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free

More information

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism Kazunori Nakayama 1, 2, Kazushi Nakao 1, 2, Yuji Takatori 1,

More information

Nephrology Dialysis Transplantation

Nephrology Dialysis Transplantation Nephrol Dial Transplant ( 1997) 12: 1223 1228 Original Article Nephrology Dialysis Transplantation Reduced calcium dialysate in CAPD patients: ecacy and limitations A. Armstrong1, J. Beer1, K. Noonan2

More information

The Effectiveness and Cost-Effectiveness of Cinacalcet for the Treatment of Hyperparathyroidism Secondary to Impaired Renal Function

The Effectiveness and Cost-Effectiveness of Cinacalcet for the Treatment of Hyperparathyroidism Secondary to Impaired Renal Function Technology Assessment Report commissioned by the NHS R&D HTA Programme on behalf of the National Institute for Health and Clinical Excellence 1. PROJECT TITLE Final Protocol August 2005 The Effectiveness

More information

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study Fernstrom, Anders; Giaever, Jan; Granroth, Barbara; Hylander,

More information

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD

More information

Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS

Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS Nephrol Dial Transplant (2007) 22: 1658 1664 doi:10.1093/ndt/gfm008 Advance Access publication 13 February 2007 Original Article Hypercalcaemia is associated with poor mental health in haemodialysis patients:

More information

Tenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia

Tenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia , a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson- Zachrisson,

More information

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority

More information

What Are the Targets in CKD-MBD?

What Are the Targets in CKD-MBD? Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital

More information

Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2

Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2 Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and

More information

Renal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young

Renal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney

More information

Ying Liu, 1 Wen-Chin Lee, 2 Ben-Chung Cheng, 2 Lung-Chih Li, 2 Chih-Hsiung Lee, 2 Wen-Xiu Chang, 1 and Jin-Bor Chen 2. 1.

Ying Liu, 1 Wen-Chin Lee, 2 Ben-Chung Cheng, 2 Lung-Chih Li, 2 Chih-Hsiung Lee, 2 Wen-Xiu Chang, 1 and Jin-Bor Chen 2. 1. BioMed Research International Volume 2016, Article ID 1523124, 7 pages http://dx.doi.org/10.1155/2016/1523124 Research Article Association between the Achievement of Target Range CKD-MBD Markers and Mortality

More information

Outline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010

Outline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010 Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,

More information

2.0 Synopsis. ABT-358/Paricalcitol M Clinical Study Report R&D/09/1255. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. ABT-358/Paricalcitol M Clinical Study Report R&D/09/1255. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Title of Study: Late Phase II Study of Paricalcitol Injection Dose-response study of paricalcitol injection in chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism

More information

Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol

Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target

More information

Secondary hyperparathyroidism an Update on Pathophysiology and Treatment

Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism

More information

Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy

Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy SAGE-Hindawi Access to Research International Nephrology Volume 211, Article ID 246734, 6 pages doi:1.461/211/246734 Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism

More information

Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management

Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Complete this course and earn 1 CME POINT Dr. HO Chung Ping MBBS (HK), MRCP, FRCP (Glas, Edin), FHKCP,

More information

Mineral and bone disorder (MBD) affects the majority

Mineral and bone disorder (MBD) affects the majority Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients Mark D. Danese,* Vasily Belozeroff, Karen Smirnakis, and Kenneth J. Rothman *Outcomes Insights, Inc., Newbury Park, California;

More information

... . : ... PTH.

... . : ... PTH. IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±

More information

Management of CKD. Goce Spasovski, R. Macedonia

Management of CKD. Goce Spasovski, R. Macedonia Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD

More information

KDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke

KDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke Unité 1088 de l Inserm UFR de Médecine et de Pharmacie Jules Verne University of Picardie Amiens, France Poten2al conflicts of interest Research support:

More information

Clinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Sensipar) Reference Number: CP.PHAR.61 Effective Date: 05.01.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012 Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco

More information

Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA

Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA Volume 11 Number 5 2008 VALUE IN HEALTH Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA Joshua A. Ray, MSc,

More information

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) Draft Labeling Package Insert Not Actual Size BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) DESCRIPTION: Full Size: Each opaque capsule with a white cap and white body is spin printed

More information

Opinion 23 April 2014

Opinion 23 April 2014 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 April 2014 MIMPARA 30 mg, film-coated tablet B/14 (CIP: 365 154 8) B/28 (CIP: 365 155 4) B/30 (CIP: 365 157 7)

More information

OPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura

OPEN.  Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance

More information

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man

More information

Advances in Peritoneal Dialysis, Vol. 29, 2013

Advances in Peritoneal Dialysis, Vol. 29, 2013 Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate

More information

IMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia

IMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia IMPLEMENTATION OF THE CKD-MBD GUIDELINES Introduction INTO CLINICAL to Renagel PRACTICE Goce Spasovski, R. Macedonia Antalya, Turkey, September 16 2012 Session Objectives Guidelines needs and controversy

More information

PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL

PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide

More information

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD

More information

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,

More information

Parathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients at Al-Shifa Hospital, Gaza-Palestine

Parathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients at Al-Shifa Hospital, Gaza-Palestine IUG Journal of Natural and Engineering Studies Vol.22,No.1, pp 97-110 2014, ISSN 1726-6807, http://www.iugaza.edu.ps/ar/periodical/ Parathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients

More information

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease

More information

Calcium Management for Patients Receiving Extended Duration Hemodialysis

Calcium Management for Patients Receiving Extended Duration Hemodialysis Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1

More information

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.

More information

Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials

Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C. Craig, MBChB, PhD, Grahame J.

More information

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) Kidney International, Vol. 65 (2004), pp. 1914 1926 Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) WAJEH Y. QUNIBI,ROBERT E. HOOTKINS,LAVETA

More information

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist

More information

Literature Scan: Phosphate Binders

Literature Scan: Phosphate Binders Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION

THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory

More information